![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.pharmaceutical-technology.com/features/first-oral-glp-1-type-2-diabetes/
https://endpts.com/eli-lilly-picks-up-an-oral-glp-1-from-a-big-roche-sub-for-50m-in-cash-plus-deal-and-its-not-a-peptide/
https://www.fiercepharma.com/ada-lilly-s-trulicity-bests-novo-s-victoza-az-s-bydureon-real-world-study
https://www.drugdeliverybusiness.com/astrazenecas-once-weekly-diabetes-drug-wins-expanded-fda-approval/
https://www.fiercepharma.com/regulatory/novo-wins-fda-blessing-for-ozempic-a-weekly-diabetes-med-carrying-big-expectations
http://www.fiercepharma.com/marketing/glp-1-trailer-bydureon-gets-a-facelift-but-can-it-stand-out-a-market-s-only-getting
http://www.fiercepharma.com/pharma/easd-did-astrazeneca-s-bydureon-outcomes-trial-design-hurt-its-chance-at-a-cv-win
http://www.fiercepharma.com/pharma/az-jumps-pay-for-performance-bandwagon-brilinta-bydureon-harvard-pilgrim-deals
http://www.reuters.com/article/us-astrazeneca-asthma-idUSKBN18I2CC
http://www.fiercepharma.com/pharma-asia/az-taps-3sbio-for-help-driving-sales-two-diabetes-drugs-china
http://www.fiercepharma.com/pharma/astrazeneca-teva-settle-byetta-patent-suit-generics-their-way
http://www.fiercebiotech.com/story/novo-nordisks-weekly-diabetes-drug-goes-5-5-phase-iii/2016-02-24
http://www.reuters.com/article/us-health-diabetes-drugs-idUSKBN0TQ2PV20151207#WbYYwaJYBwzDj3vb.97
http://www.prnewswire.com/news-releases/intarcia-presents-results-from-two-successful-phase-3-trials-for-itca-650-its-investigational-therapy-in-type-2-diabetes-at-51st-easd-300143957.html
http://www.fiercepharma.com/story/azs-bydureon-tops-doc-payments-list-22b/2015-07-08